ADVANTAGES IN COMBINATION CHEMOTHERAPY USING CISPLATIN AND ITS ANALOGS FOR HUMAN TESTICULAR-TUMOR XENOGRAFTS

被引:6
作者
HIDA, S [1 ]
OKADA, K [1 ]
YOSHIDA, O [1 ]
机构
[1] KYOTO UNIV,FAC MED,DEPT UROL,54 SHOGOIN KAWAHARA MACHI,SAKYO KU,KYOTO 606,JAPAN
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1990年 / 81卷 / 04期
关键词
Cisplatin; Cisplatinum analogue; Combination chemotherapy;
D O I
10.1111/j.1349-7006.1990.tb02585.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The antitumor effects and toxicities of combination chemotherapies using cisplatin (CDDP) and its analogues were compared with those of single drug therapies. Congenitally athymic nude BALB/c (nu/nu) mice were used to estimate antitumor activities of these compounds against human testicular tumor (Ht‐14) xenografts and hetero‐BALB/c (nu/+) mice were used to evaluate the toxic effects of the drugs. Combination therapy with half dosages of CDDP and carboplatin (JM8) (CDDP: 2, JM8: 20 mg/kg/day for 5 days), or of CDDP and (glycolato‐O, O′)‐diammineplatinum (II) (254S) (CDDP: 2, 254S: 4 mg/kg/day for 5 days), resulted in significant tumor regression. The combination of CDDP and JM8 had the highest therapeutic efficacy while the CDDP and 254S combination had a lower antitumor potency. In addition, the toxicities of the combination therapies were lower than what was produced by the highest dosage of CDDP (4 mg/kg/day for 5 days). These results demonstrated that the antitumor activities of these combination chemotherapies were equal or superior to the activity of CDDP or an analogue alone, and that the toxicities produced by these combinations were more manageable than those produced by single drug therapies. Copyright © 1990, Wiley Blackwell. All rights reserved
引用
收藏
页码:425 / 430
页数:6
相关论文
共 18 条
[1]  
HARSTRICK A, 1989, CANCER, V63, P1079, DOI 10.1002/1097-0142(19890315)63:6<1079::AID-CNCR2820630607>3.0.CO
[2]  
2-J
[3]   CHARACTERISTICS AND CHEMOTHERAPEUTIC SENSITIVITY OF A HUMAN TESTICULAR CANCER GROWN IN ARTIFICIALLY IMMUNOSUPPRESSED MICE [J].
LAPIS, P ;
KOPPER, L ;
BODROGI, I ;
SUGAR, J ;
LAPIS, K ;
ECKHARDT, S .
ONCOLOGY, 1985, 42 (02) :112-118
[4]  
OKADA K, 1984, Acta Urologica Japonica, V30, P1749
[5]   A RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY-V A HIGH-DOSE CHEMOTHERAPY REGIMEN IN THE TREATMENT OF POOR PROGNOSIS NONSEMINOMATOUS GERM-CELL TUMORS [J].
OZOLS, RF ;
IHDE, DC ;
LINEHAN, WM ;
JACOB, J ;
OSTCHEGA, Y ;
YOUNG, RC .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (06) :1031-1040
[6]   ADVANCED SEMINOMA - TREATMENT WITH CIS-PLATINUM-BASED COMBINATION CHEMOTHERAPY OR CARBOPLATIN (JM8) [J].
PECKHAM, MJ ;
HORWICH, A ;
HENDRY, WF .
BRITISH JOURNAL OF CANCER, 1985, 52 (01) :7-13
[7]   PHASE-I STUDY OF CARBOPLATIN GIVEN ON A 5-DAY INTRAVENOUS SCHEDULE [J].
ROZENCWEIG, M ;
NICAISE, C ;
BEER, M ;
CRESPEIGNE, N ;
VANRIJMENANT, M ;
LENAZ, L ;
KENIS, Y .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (10) :621-626
[8]  
SAMSON MK, 1984, CANCER, V53, P1029, DOI 10.1002/1097-0142(19840301)53:5<1029::AID-CNCR2820530503>3.0.CO
[9]  
2-Z
[10]   PHARMACOKINETICS OF (GLYCOLATO-0,0')-DIAMMINE PLATINUM(II), A NEW PLATINUM DERIVATIVE, IN COMPARISON WITH CISPLATIN AND CARBOPLATIN [J].
SASAKI, Y ;
TAMURA, T ;
EGUCHI, K ;
SHINKAI, T ;
FUJIWARA, Y ;
FUKUDA, M ;
OHE, Y ;
BUNGO, M ;
HORICHI, N ;
NIIMI, S ;
MINATO, K ;
NAKAGAWA, K ;
SAIJO, N .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 23 (04) :243-246